(Q44667232)

5 December 2017

Sodium stibogluconate cardiotoxicity and safety of generics (English)

1 reference

5 December 2017

sodium stibogluconate

1 reference

4

1 reference

5 December 2017

Rijal S

1

1 reference

5 December 2017

Chappuis F

2

1 reference

5 December 2017

Singh R

3

1 reference

5 December 2017

Loutan L

5

1 reference

5 December 2017

Koirala S

6

1 reference

5 December 2017

1 September 2003

1 reference

Transactions of the Royal Society of Tropical Medicine and Hygiene

5 December 2017

1 reference

5 December 2017

97

1 reference

5 December 2017

5

1 reference

5 December 2017

597-598

1 reference

Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.

5 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2980043-3

7 January 2021

A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2980043-3

7 January 2021

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2980043-3

7 January 2021

A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2980043-3

7 January 2021

Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2980043-3

7 January 2021

10.1016/S0035-9203(03)80043-3

Identifiers

DOI

1 reference

5 December 2017

1 reference